Cadila Pharma’s Vitamin D therapy addresses a critical gap in deficiency management, combining proven formulations with innovation to support safer, more effective, and consistent patient outcomes.
Vitamin D deficiency represents a significant global public health issue, affecting an estimated one billion people worldwide. In India, despite abundant sunshine, the prevalence is alarming, with numerous studies reporting rates of up to 90% in the general population. The deficiency is associated with its critical role in calcium and phosphate homeostasis, leading to skeletal disorders like rickets in children and osteomalacia or osteoporosis in adults, which results in weak bones and increased fracture risk.
Beyond bone health, the deficiency is linked to an elevated risk of chronic diseases, including cardiovascular diseases, type 2 diabetes, and autoimmune disorders, contributing to a substantial overall burden. Contributing factors in India include inadequate dietary intake (as few foods are fortified), limited sun exposure due to urban, indoor lifestyles and cultural practices, and increased skin pigmentation.
Our therapeutic focus
Focused approach to Vitamin D deficiency management, we bring together established, formulation-led advancements to support effective patient care.
Our range of solutions starts with a Vitamin D dose of 60,000 IU to 600,000 IU to combat Vitamin D deficiency. Along with oral cholecalciferol formulations (sachet, softgels, nano), we also developed the world’s first aqueous Vitamin D₃ injection. Its innovative formulation ensures painless administration, superior absorption, and faster correction of deficiency, offering a safer and more effective solution.
The first Vitamin D brand we launched dates back to 1969, Calcirol Sachet. With over 55 years of trusted expertise, Calcirol has become a cornerstone in India's healthcare landscape. Backed by rigorous scientific research and clinical evidence, it has empowered more than 100 million individuals to achieve optimal vitamin D levels, promoting bone health and overall well-being.
Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication.
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
